US EditionPublished • loading... • Updated
Celltrion’s Omlyclo gains traction across Europe
Summary by News Article Insiders
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Celltrion’s Omlyclo gains traction across Europe
Celltrion‘s biosimilar Omlyclo is rapidly expanding its prescription base across Europe. [Photo courtesy of Celltrion] South Korea’s Celltrion announced on April 13 that its biosimilar Omlyclo, developed for the treatment of chronic spontaneous urticaria and allergic asthma, is rapidly expanding its prescription base across Europe. Omlyclo, a biosimilar of omalizumab, has been gaining momentum as a first mover in multiple European markets, with …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
